Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension

Boehringer Ingelheim

Status: Completed

Conditions: Hypertension

Treatments: Drug: Micardis®

Study type: Observational

Funder types: Industry

Identifiers

NCT02176850

502.314

Details and patient eligibility

About

This post-marketing surveillance study was designed to supplement under conditions of normal clinical practice the data on the safety, tolerability and efficacy of Micardis® collected during the clinical studies.

Enrollment: 19,870 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients of both sexes with essential hypertension and a minimum age of 18 years

Exclusion Criteria: (Not applicable)

Trial design

19,870 participants in 1 patient group

Micardis®

Treatment:

Drug: Micardis®